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Abstract
Objective: This retrospective study determined for the first time the role of baseline antral follicle count (AFC) and serum
anti-Mullerian hormone (AMH) level in the first in-vitro fertilisation (IVF) cycle in predicting cumulative live birth from one
stimulation cycle.
Methods:We studied 1,156 women (median age 35 years) undergoing the first IVF cycle. Baseline AFC and AMH level on the
day before ovarian stimulation were analysed. The main outcome measure was cumulative live birth in the fresh plus all the
frozen embryo transfers after the same stimulation cycle.
Results: Serum AMH was significantly correlated with AFC. Both AMH and AFC showed significant correlation with age and
ovarian response in the stimulated cycle and total number of transferrable embryos. Baseline AFC and serum AMH were
significantly higher in subjects attaining a live birth than those who did not in the fresh stimulated cycle, as well as those
attaining cumulative live birth. There was a significant trend of higher cumulative live birth rate in women with higher AMH
or AFC. However, logistic regression revealed that both AMH and AFC were not significant predictors of cumulative live
birth after adjusting for age and number of embryos available for transfer. Considering only one single predictor, the areas
under the ROC curves for AMH (0.646, 95% CI 0.616–0.675) and age (0.648, 95% CI 0.618–0.677) were slightly higher than
that for AFC (0.617, 95% CI 0.587–0.647) in predicting cumulative live birth. However, a model combining AMH (with or
without AFC) and age of the women only classified an addition of less than 2% of subjects correctly compared to the model
with age alone.
Conclusion: Baseline AFC and serum AMH have only modest predictive performance on the occurrence of cumulative live
birth, and may not give additional value on top of the women’s age.
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Introduction
In assisted reproduction programmes, a number of parameters
known as ovarian reserve markers, such as serum follicle
stimulating hormone (FSH) concentration, antral follicle count
(AFC) and serum anti-Mullerian hormone (AMH) concentration,
are widely used to predict ovarian responses to gonadotrophin
stimulation during in-vitro fertilization (IVF) treatment. These
markers may help to decide on the initial dose and regimen of
stimulation [1,2]. Among the commonly used ovarian reserve
markers, AFC and AMH provide the best performance in
predicting both poor and excessive ovarian response [3,4,5].
However, most reports consistently showed a poor predictive value
of these markers on pregnancy rate in the fresh IVF cycle [4,6].
AMH, also known as Mullerian-inhibiting substance, is a
dimeric glycoprotein that belongs to the transforming growth
factor-beta family. It is involved in the regression of the Mullerian
ducts during development of the male fetus [7]. In the adult
female, AMH is exclusively produced by granulosa cells of
preantral and small antral follicles, and has been shown to
correlate excellently with the primordial follicle pool [8]. Hence it
would serve as an ovarian reserve marker. Since AMH performs
equally well, if not better, than AFC in predicting ovarian response
and that it is both operator- and menstrual cycle-independent,
there has been a growing trend to adopt AMH assay as the first-
line ovarian reserve test [2,9].
In modern-day assisted reproduction programmes, embryo
cryopreservation has become an integral component. It allows the
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storage and subsequent usage of surplus good quality embryos in
frozen-thawed embryo transfer (FET) cycles. Hence, to evaluate
the outcome of an IVF cycle, it would be more logical to consider
the cumulative live birth rate from the fresh and all FET cycles
combined, instead of merely looking at the single fresh cycle
outcome.
There have been limited data on the role of these ovarian
reserve markers in predicting cumulative pregnancy or live birth
rates in IVF programmes. A study looked at the use of AMH on
Day 6 of ovarian stimulation in predicting cumulative ongoing
pregnancy outcome [10]. Yet AMH levels can be altered after
commencement of ovarian stimulation [11,12,13], and it may be
of more practical value to study AMH level before commencement
of stimulation, and to look at live birth as the outcome which
would be what patients are ultimately concerned about.
Therefore, we conducted this retrospective analysis to evaluate
the role of baseline AFC and AMH in the first stimulated IVF
cycle in predicting the cumulative live birth from the stimulated
cycle and all subsequent FET cycles derived from that stimulated
cycle.
Materials and Methods
Subject selection
We reviewed all first IVF cycles carried out between January
2007 and December 2009 at the Centre of Assisted Reproduction
and Embryology, The University of Hong Kong – Queen Mary
Hospital, Hong Kong. Cycles carried out for pre-implantation
genetic diagnosis or those using donor oocytes were excluded from
this analysis. Clinical details of all treatment cycles were
prospectively entered into a computerized database, which were
retrieved for analysis.
Ethics statement
An ethics approval was obtained from the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster for this retrospective study to be carried out
using existing patient data in an anonymous manner without
requiring written consent from individual patients. The project did
not involve any additional intervention or modification from the
standard treatment.
Stimulation cycle, AFC and AMH determination
All patients attended the clinic for blood test and pelvic
ultrasound examination at the beginning of the IVF treatment
cycle before commencing ovarian stimulation. Transvaginal
scanning was performed using a 5 MHz vaginal probe (Voluson
730H, GE Healthcare, Wisconsin, USA) to determine AFC (2–
9 mm) in both ovaries. Blood was taken for routine oestradiol (E2)
assay, and residual serum samples were stored at 220uC. For the
current study, these archived serum samples were retrieved and
assayed for AMH using the AMH Gen II ELISA kit (Beckman
Coulter, Webster, TX, USA; catalogue number A79765). The
assay has a sensitivity of 0.08 ng/ml (0.6 pmol/l), and intra- and
inter-assay coefficients of variation of less than 5.4 and 5.6%.
All subjects were treated either with the long GnRH agonist
protocol or the GnRH antagonist protocol for pituitary down-
regulation, with the latter mostly for selected patients with poor
ovarian reserve. In the long GnRH agonist protocol, the women
received buserelin (SuprecurH, Hoechst, Frankfurt, Germany)
nasal spray 150 mg four times a day starting from the mid-luteal
phase of the cycle preceding the treatment cycle, and received
human menopausal gonadotrophin (HMG) or recombinant FSH
for ovarian stimulation after return of a period. In the GnRH
antagonist protocol, after confirming a basal serum oestradiol
level, ovarian stimulation was started. The women received
ganirelix or cetrorelix 250 mg daily starting from the sixth day of
stimulation. The initial dose of stimulation was determined
according to the baseline AFC (AFC$15: 150 IU per day; AFC
between 6 and 14: 300 IU for the first two days followed by
150 IU daily; AFC#5: 300–450 IU for the first two days followed
by 225 IU daily). Human chorionic gonadotrophin (hCG)
(PregnylH 5000 or 10000 units or OvidrelH 250 mg) was given
when the mean diameter of the leading follicle reached 18 mm
and there were at least 3 follicles reaching a mean diameter of
16 mm or above, followed by transvaginal ultrasound-guided
oocyte retrieval 36 hours later. Fertilisation was carried out in-
vitro either by conventional insemination or intracytoplasmic
sperm injection (ICSI) depending on semen parameters.
Subjects were allowed to have replacement of at most two
embryos two days post-fertilisation. Embryo transfer (ET) was
performed under transabdominal ultrasound guidance using a soft
catheter (Sydney IVF Embryo Transfer CatheterH, Cook, Indiana,
USA). Fresh embryo transfer would be cancelled and all the
embryos with good quality were cryopreserved on day 2 after the
Table 1. Correlation of AMH and AFC with ovarian stimulation parameters in fresh stimulation cycle.
Parameter Serum AMH AFC
Correlation coefficient p-value Correlation coefficient p-value
Age of women 20.321 ,0.001* 20.335 ,0.001*
Body mass index 0.001 0. 969 0.035 0.238
Duration of stimulation 20.232 ,0.001* 20.224 ,0.001*
Total dose of gonadotrophin 20.590 ,0.001* 20.683 ,0.001*
No of follicles .= 16 mm 0.548 ,0.001* 0.449 ,0.001*
Peak serum oestradiol 0.529 ,0.001* 0.410 ,0.001*
No. of oocytes retrieved 0.629 ,0.001* 0.527 ,0.001*
No. of transferrable embryos 0.438 ,0.001* 0.364 ,0.001*
No. of top quality embryos# 0.341 ,0.001* 0.321 ,0.001*
*statistically significant (p,0.005).
#defined as number of blastomeres $4 with grading 1 or 2 (data available in 593 subjects only).
doi:10.1371/journal.pone.0061095.t001
AFC, AMH and Cumulative Live Birth in IVF
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61095
retrieval if the subject had symptoms suggestive of ovarian
hyperstimulation syndrome (OHSS) or serum E2 concentration
on the day of hCG injection was .20,000 pmol/L.
Cryopreservation and frozen-thawed embryo transfer
(FET)
Embryos were graded based on the number/regularity of
blastomeres and the degree of fragmentation [14]. Surplus
embryos of grades 1 to 4 were frozen on the day of ET, whereas
embryos with poor quality (Grades 5 and 6) were discarded.
Cryopreservation was performed by a slow freezing protocol using
a programmable freezer (Planer Products Ltd.; Sunbury-On-
Thames, UK) in straws of two. The details of the freezing and
thawing protocols were reported previously [15]. The frozen
embryos were thawed on the morning of FET. Embryos were
discarded if more than 50% of the original blastomeres were lysed
or degenerated upon thawing. Frozen-thawed embryos were
transferred in natural cycles in ovulatory subjects. LH surge was
determined by serial blood tests, and FET was performed on the
third day after LH surge. For anovulatory subjects, FET was
carried out in either clomiphene-induced or hormone replacement
cycles. A maximum of two frozen embryos were allowed to be
transferred in any one FET cycle.
Pregnancy outcome
A urine pregnancy test was done 16 days after embryo transfer.
Pregnant women were offered an ultrasound examination 10–14
days later to confirm intrauterine pregnancy and the number of
gestational sacs present. Pregnancy outcome was traced from all
pregnant women by postal questionnaire or by phone.
Statistical analysis
The primary outcome measure was the cumulative live birth in
the fresh and all FET cycles combined following the same index
stimulation cycle. The age of the women used in analysis referred
to the time of starting ovarian stimulation. Non-normally
Table 2. Comparison of demographic and clinical characteristics of subjects with or without achieving live birth in the fresh IVF
cycle.
Parameter
Subjects achieving a live birth in
fresh IVF cycle (n=383)
Subjects not achieving a live birth in
fresh IVF cycle (n=643) P value
Age (years) 34.0 (32.0–37.0) 36.0 (34.0–38.0) ,0.001*
Body mass index (kg/m2) 21.0 (19.5–23.2) 21.2 (19.6–23.1) 0.927
Serum AMH (ng/ml) 3.27 (1.75–5.65) 2.64 (1.32–4.69) ,0.001*
Antral follicle count 10.0 (6–15) 9.0 (5–13) 0.001*
Cause of subfertility
Male factor
Tuboperitonal factor
Endometriosis
Anovulation
Unexplained
Mixed factors
236 (61.6%)
49 (12.8%)
19 (5.0%)
6 (1.6%)
19 (5.0%)
54 (14.0%)
371 (57.7%)
98 (15.2%)
25 (3.9%)
1 (0.2%)
41 (6.3%)
107 (16.7%)
0.056
(Fisher’s Exact test)
No. of embryos replaced
One
Two
22 (5.7%)
361 (94.3%)
116 (18.0%)
527 (82.0%)
,0.001 (Fisher’s
Exact test)
Continuous data are expressed as median (interquartile range).
*statistically significant.
Mann-Whitney U test unless otherwise stated.
doi:10.1371/journal.pone.0061095.t002
Table 3. Binary logistic regression analysis of factors for prediction of (a) a live birth in the fresh IVF cycle and (b) a cumulative live
birth from the fresh plus all frozen-thawed transfer cycles combined after the same index stimulation cycle.
(a) Factors to predict a live birth in the fresh IVF cycle B Exp(B), 95% CI P-value
AFC 20.002 0.998, 0.972–1.025 0.880
AMH 0.020 1.020, 0.966–1.077 0.470
Age 20.122 0.885, 0.849–0.923 ,0.001*
Number of embryos transferred 1.236 3.441, 2.124–5.577 ,0.001*
(b) Factors to predict a cumulative live birth B Exp(B), 95% CI P-value
AFC 20.004 0.996, 0.968–1.025 0.791
AMH 0.003 1.003, 0.995–1.012 0.441
Age 20.129 0.879, 0.841–0.918 ,0.001*
Total number of transferrable embryos 0.259 1.295, 1.228–1.366 ,0.001*
*statistically significant.
doi:10.1371/journal.pone.0061095.t003
AFC, AMH and Cumulative Live Birth in IVF
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distributed continuous variables were expressed as median
(interquartile range) unless otherwise stated. Continuous and
categorical variables were compared between groups using Mann-
Whitney test and Fisher’s Exact test respectively. Logistic
regression analysis was used to examine factors predicting
cumulative live birth, and receiver-operator characteristic (ROC)
curves were compared for different ovarian reserve markers in
predicting cumulative live birth. Statistical analysis was carried out
using the Statistical Program for Social Sciences (SPSS Inc.,
Version 15.0, Chicago, U.S.A.) and MedCalc (Version 12,
Belgium). The two-tailed value of P ,0.05 was considered
statistically significant.
Results
Of the 1,156 subjects who underwent the first IVF cycle during
the study period, 1,050 (90.8%) were treated on the long GnRH
agonist protocol, and the remaining 106 (9.2%) on the GnRH
antagonist protocol. The age and body mass index (BMI) [median
(interquartile range)] of our subjects were 35 (33–38) years and
21.2 (19.6–23.1) kg/m2 respectively. The cause of subfertility
included male factor (687; 59.4%), tubo-peritoneal factor (159;
13.8%), endometriosis (54; 4.7%), anovulation (8; 0.7%), unex-
plained (62; 5.4%) and mixed causes (186; 16.0%).
Correlation of AFC and AMH with other demographic
and clinical characteristics
There was a significant correlation between serum AMH and
AFC (R=0.780, p,0.001). As shown in Table I, both serum
AMH and AFC were significantly correlated with the women’s
age, duration of stimulation, total dose of gonadotrophin used,
number of mature-sized follicles ($16 mm), peak serum E2
concentration, number of oocytes retrieved and transferrable
embryos obtained (for fresh transfer and/or freezing) and number
of top quality embryos (p,0.001 for all). There was no significant
correlation between serum AMH or AFC with BMI.
AFC, AMH and live birth in the fresh cycle
There were 1,026 subjects (88.8%) who had fresh ET. Among
them, 510 (49.7%) had a positive pregnancy test in the fresh cycle,
and 383 (37.3%) attained live birth. Among those who were
pregnant, there was no significant difference (p.0.05) in AFC and
serum AMH between those who miscarried and those who had
live birth. The clinical and demographic characteristics of subjects
with or without a live birth in the fresh cycle are compared in
Table II. Subjects who attained a live birth were significantly
younger (median 34.0 vs 36.0 years), had significantly higher AFC
(median 10.0 vs 9.0) and serum AMH [median 3.27 ng/ml
(23.3 pmol/l) vs 2.64 ng/ml (18.8 pmol/l)], and more of them had
double embryo transfer (94.3% vs 82.0%). There were no
statistically significant differences in BMI between subjects who
had live birth in the fresh cycle or not, nor in the distribution of the
cause of subfertility.
Binary logistic regression using the enter method was used to
analyse the prediction on live birth in the fresh IVF cycle by the
women’s age, AFC, serum AMH and number of embryos
replaced. The women’s age and the number of embryos replaced,
but not AFC or serum AMH, were the significant factors which
independently predicted the likelihood of a live birth in the fresh
cycle (Table IIIa).
Figure 1A shows the ROC curve analysis of AFC and serum
AMH in predicting a live birth in the fresh cycle. The area under
the curve (AUC) for AFC and serum AMH were 0.559 (95% CI
0.528–0.589) and 0.575 (95% CI 0.545–0.606) respectively, which
were both inferior (p,0.05, Delong analysis) to that for age of the
women (0.629, 95% CI 0.598–0.658).
AFC, AMH and cumulative live birth
Among the subjects included in this study, 1,038 (89.8%) had
completed replacement of all available embryos and with a live
birth outcome available. Of them, 558 (53.8%) attained live birth
cumulatively from the fresh plus all FET cycles after the same
index IVF cycle.
Table IV depicts the demographic and clinical characteristics of
subjects who had a cumulative live birth and those who did not.
Subjects who attained a cumulative live birth were significantly
younger (median 34.0 vs 36.0 years), had significantly higher AFC
(median 11.0 vs 8.0) and serum AMH [median 3.7 ng/ml
(26.4 pmol/l) vs 2.3 ng/ml (16.4 pmol/l), and had significantly
higher number of transferrable embryos (median 5 vs 2). The
minimum values of AFC and serum AMH in subjects who
attained a cumulative live birth were 0 and 0.15 ng/ml (1.1 pmol/
Figure 1. Receiver operator characteristic (ROC) curve analysis.
Panal (A) shows the ROC curves of antral follicle count (AFC), serum
AMH concentration and age of the women in predicting live birth from
the fresh stimulation cycle, while Panal (B) shows those in predicting
cumulative live birth from fresh and all frozen embryo transfers after the
same index stimulation cycle.
doi:10.1371/journal.pone.0061095.g001
AFC, AMH and Cumulative Live Birth in IVF
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l) respectively (vs 0 and ,0.08 ng/ml (,0.6 pmol/l) respectively
in those without a cumulative live birth).
Figure 2 shows the cumulative live birth rate in subjects
categorised according to baseline AMH and AFC. There was an
overall significant trend of a higher cumulative live birth rate in
subjects with higher serum AMH levels or AFC compared to those
at the lower end (p,0.001 for both AMH and AFC, x2 test for
trend).
When the women’s age, AFC, serum AMH and total number of
transferrable embryos derived from the index IVF cycle were
entered into the binary logistic regression model using the enter
method, the women’s age and total number of transferrable
embryos, but not AFC or AMH, were significant independent
factors in predicting a cumulative live birth (Table IIIb).
We further analysed the predictive performance of AFC and
AMH in additional to age of the women versus age alone on
cumulative live birth. (Table V). The addition of AMH, but not
AFC, to age provided additional predictive value compared to
using age alone. However, although statistically significant
(p,0.05, Delong analysis), the model combining the women’s
age and AMH, with or without AFC, only respectively classified
an additional 1.7% or 1.9% of subjects correctly compared to the
model with age alone.
Figure 1B shows ROC curve analysis of AFC, serum AMH and
age in predicting a cumulative live birth. The AUC for serum
AMH and age were 0.646 (95% CI 0.616–0.675) and 0.648 (95%
CI 0.618–0.677) respectively, which were both significantly higher
(p,0.05) than that for AFC (0.617, 95% CI 0.587–0.647).
Discussion
In assisted reproduction programmes, ovarian reserve markers
such as FSH, AFC, and more recently AMH, have been widely
used for predicting ovarian response and prognostic counseling.
Recent systematic reviews have suggested that AFC and AMH
were the best predictors of excessive and suboptimal ovarian
response and both had comparable performance in this regard
[4,5]. AMH has the additional benefits of being not operator-
dependent and having negligible inter-cycle variations [16], and
hence has gained increasing favour in its clinical applications [2,9].
However, the majority of reported studies consistently demon-
strated that both AFC and AMH had poor performance in
predicting pregnancy outcome in IVF cycles [4,6].
Nonetheless, most of the reported studies evaluated the
pregnancy or live birth outcome in the fresh IVF cycle only. In
modern assisted reproduction programmes, cryopreservation of
surplus embryos with subsequent transfers in thawed cycles has
become an integral part. It has been estimated that in programmes
which incorporate embryo cryopreservation, up to 42% of all
conceptions could be derived from FET [17]. As there is a recent
trend in reducing the number of embryos replaced to reduce the
risk of multiple pregnancy, the number of live births from the
stimulated cycle only is not a good indicator of outcome of
treatment. Hence, we feel that it would be more meaningful to
study the cumulative live birth per stimulated cycle as the
treatment outcome. This would take into account the outcomes in
the transfer of fresh as well as frozen embryos derived from the
same index stimulation cycle, the latter of which should not be
ignored. There was one study which reported that serum AMH on
day 6 of stimulation was significantly higher in subjects attaining
cumulative ongoing pregnancy than those who did not [10].
However, it has been reported that serum AMH is suppressed
during ovarian stimulation compared to baseline level under both
GnRH agonist and antagonist protocols [11,12,13]. Practically,
measurement of the baseline AMH level before stimulation would
be of more relevance for either prognostic prediction or
individualization of gonadotrophin dosing. To our knowledge,
the current study is the first to report on the role of baseline serum
AMH and AFC in the index stimulation cycle in predicting
cumulative live birth outcome so derived in a large cohort.
Our results demonstrated that women who attained a cumu-
lative live birth had significantly higher serum AMH and AFC at
baseline before ovarian stimulation. However, the predictive
performance of both parameters on the absolute occurrence of
cumulative live birth was only modest and not better than age as
demonstrated in the ROC curves. This is obviously comprehen-
sible by observing the trend of cumulative live birth rate over serial
increase in serum AMH or AFC as shown in Figure 2. There was a
gradual increase in cumulative live birth rate in women with
higher AMH or AFC, and yet it varied over a continuum with no
clear cut-off where the cumulative live birth rate could show an
Table 4. Comparison of demographic and clinical characteristics of subjects with or without achieving a cumulative live birth from
the fresh plus all the frozen-thawed embryo transfer cycles combined after the same index stimulation cycle.
Parameter
Subjects achieving a cumulative
live birth (n =558)
Subjects not achieving a cumulative
live birth (n=480) P value
Age (years) 34 (32–37) 36 (34–38) ,0.001*
Body mass index (kg/m2 21.1 (19.5–23.1) 21.2 (19.7–23.2) 0.426
Serum AMH (ng/ml) 3.7 (1.9–6.1) 2.3 (1.1 6–4.2) ,0.001*
Antral follicle count 11 (7–16) 8 (5–12) ,0.001*
Cause of subfertility
Male factor
Tuboperitonal factor
Endometriosis
Anovulation
Unexplained
Mixed factors
348 (62.4%)
69 (12.4%)
23 (4.1%)
7 (1.3%)
31 (5.6%)
80 (14.2%)
274 (57.1%)
77 (16.0%)
22 (4.6%)
0 (0%)
27 (5.6%)
80 (16.7%)
0.048* (Fisher’s Exact
test)
Total number of transferrable embryos 5 (3–8) 2 (2–4) ,0.001*
Continuous data are expressed as median (interquartile range).
*statistically significant.
Mann-Whitney U test unless otherwise stated.
doi:10.1371/journal.pone.0061095.t004
AFC, AMH and Cumulative Live Birth in IVF
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abrupt change. Hence, it would be impossible for any set value of
AMH or AFC to predict the all-or-none occurrence of a
cumulative live birth.
Hypothetically, women with higher AMH or AFC have better
ovarian reserve and hence higher oocyte yield and a larger
potential pool of good quality embryos to be selected for transfer.
This was supported by our findings that subjects who attained
cumulative live birth had higher number of transferable embryos,
and that the latter was an independent factor predicting
cumulative live birth in logistic regression analysis. This is in line
with a recent study which suggested that the total number of good-
quality embryos and total number of transferable embryos were
the two most important predictors of cumulative clinical
pregnancy, particularly in women aged below 40 years [18].
Analysis of our data showed that the cumulative live birth rate
increased with increasing number transferrable embryos up till 15,
after which it plateaued (data not shown). The same has been
recently reported on a large cohort of 400,135 IVF treatment
cycles, in which the live birth rate in the fresh IVF cycle correlated
positively with the number of retrieved oocytes up till 15, after
which it plateaued and actually declined after going beyond 20
[19], though the study did not take into account the FETs.
Therefore, at the higher end of embryo yield, further increase in
embryo number does not necessarily mean better live birth
outcome because the occurrence of live birth is subjected to
influence by other factors as well, such as embryo quality and
endometrial receptivity.
With regard to endometrial receptivity, women with high AFC
and/or serum AMH levels are at increased risk of ovarian
hyperstimulation, and the resultant higher peak E2 levels could
have detrimental effects on endometrial receptivity [20,21]. This
may offset the potentially favourable implication of higher ovarian
response in the fresh stimulated cycle. Embryo quality is another
major issue, which seemingly cannot be predicted by either AMH
or AFC, as illustrated by previously reported studies which
revealed no consistent correlation between AMH and embryo
morphology nor aneuploidy rate [22,23,24]. Hence all these
parameters do not seem to have good prediction on the qualitative
aspect of embryo competence. Probably there is no single factor
which can precisely predict cumulative live birth outcome, which
is actually determined by the complicated interplay of multiple
factors. Indeed, among our subjects who had serum AMH
,0.5 ng/ml (,3.6 pmol/l), a cumulative live birth rate of 27%
could still be attained, and in those with AFC #1, again a
cumulative live birth rate of 22% was observed (data not shown).
Moreover, a cumulative live birth did occur with a minimum
baseline AMH level of 0.15 ng/ml (1.1 pmol/l) and AFC of zero.
We also analysed the value of adding AFC and AMH on top of
the women’s age in the prediction model for cumulative live birth.
Although statistically significant, the combined model with the
women’s age and AMH (with or without AFC) classified an
addition of less than 2% of subjects correctly compared to the
model with age alone. This very modest improvement in the
prediction may not be very meaningful clinically.
Based on our results, we would recommend that it is not
worthwhile to use any of the ovarian reserve markers including
serum AMH or AFC as the basis to exclude subjects from
attempting assisted reproduction treatments, and when used for
prognostic counselling the women should understand the limita-
tions and imprecision of these indices in anticipating the treatment
outcome.
Inherent to the retrospective design, our results might have been
subjected to verification bias, as the gonadotrophin dosing regimen
Figure 2. Cumulative live birth rate stratified according to
serum AMH and antral follicle count (AFC). Panal (A) shows the
association between serum AMH level and cumulative live birth rate
from the fresh plus all frozen embryo transfer cycles combined, whereas
Panal (B) shows that between AFC and cumulative live birth rate. There
was a significant trend of increase across the bars from the lower to the
higher ends of AMH and antral follicle count (p,0.001 for both, x2 test
for trend).
doi:10.1371/journal.pone.0061095.g002
Table 5. Comparison of AMH, AFC in addition to age and age
only in predicting cumulative live birth by logistic regression
analysis.
Model Predictors OR (95% CI)
Classification
rate #AUC (95% CI)
A Age 0.86 (0.81–0.92) 63.6% a0.69 (0.64–0.74)
AMH 1.02 (0.98–1.07)
AFC 1.06 (0.97–1.15)
B Age 0.86 (0.80–0.92) 63.8% b0.69 (0.63–0.74)
AMH 1.09 (1.02–1.16)
C Age 0.86 (0.81–0.92) 61.7% c0.68 (0.63–0.73)
AFC 1.04 (1.01–1.07)
D Age 0.84 (0.79–0.90) 61.9% 0.66 (0.60–0.71)
#The AUCs were derived from the logistic regression models.
ap=0.026 compared with AUC for model A and AUC for model D.
bp= 0.018 compared with AUC for model B and AUC for model D.
cp= 0.083 compared with AUC for model C and AUC for model D.
doi:10.1371/journal.pone.0061095.t005
AFC, AMH and Cumulative Live Birth in IVF
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e61095
has been preselected based on AFC in our protocol. We have
repeated the analysis on the subgroup of subjects stimulated with
an average daily dose of 225 IU or more, which presumably gave
maximal stimuation. There was no significant difference in the
areas under the ROC curve for AMH, AFC and age in predicting
cumulative live birth (data not shown).
The strength of our study was the inclusion of a large cohort of
subjects over a wide age range from 22 to 45 years with diversified
ovarian reserve to enhance generalisability. Although some of the
subjects had not completed replacement of all available frozen
embryos and were hence excluded from the cumulative live birth
analysis, they did not differ significantly from the included subjects
in sociodemographic parameters.
In conclusion, our results confirmed a good correlation of
baseline serum AMH and AFC with ovarian response parameters
in IVF treatment. Baseline AFC and serum AMH were
significantly higher in subjects attaining cumulative live birth,
and there was a significant trend of increase in cumulative live
birth rate in women with higher AMH or AFC. However, the
predictive role of AFC and AMH on absolute occurrence of
cumulative live birth was only modest and may not give much
additional value on top of the women’s age.
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